Immix Biopharma (IMMX) Stock Forecast, Price Target & Predictions
IMMX Stock Forecast
Immix Biopharma stock forecast is as follows: an average price target of $7.00 (represents a 222.58% upside from IMMX’s last price of $2.17) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
IMMX Price Target
The average price target for Immix Biopharma (IMMX) is $7.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential 222.58% upside from IMMX's last price of $2.17.
IMMX Analyst Ratings
According to 1 Wall Street analysts, Immix Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for IMMX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Immix Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 01, 2024 | Robert Burns | H.C. Wainwright | $7.00 | $1.98 | 253.54% | 222.58% |
The latest Immix Biopharma stock forecast, released on Jul 01, 2024 by Robert Burns from H.C. Wainwright, set a price target of $7.00, which represents a 253.54% increase from the stock price at the time of the forecast ($1.98), and a 222.58% increase from IMMX last price ($2.17).
Immix Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $7.00 |
| Last Closing Price | $2.17 | $2.17 | $2.17 |
| Upside/Downside | -100.00% | -100.00% | 222.58% |
In the current month, the average price target of Immix Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immix Biopharma's last price of $2.17. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 01, 2024 | H.C. Wainwright | Buy | Initialise |
Immix Biopharma's last stock rating was published by H.C. Wainwright on Oct 03, 2024. The company gave IMMX a "Buy" rating, the same as its previous rate.
Immix Biopharma Financial Forecast
Immix Biopharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Immix Biopharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMMX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Immix Biopharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict IMMX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immix Biopharma's previous annual EBITDA (undefined) of $NaN.
Immix Biopharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-3.53M | $-3.83M | $-4.12M | $-3.83M | $-4.12M | $-4.71M | $-4.32M |
| High Forecast | $-3.53M | $-3.83M | $-4.12M | $-3.83M | $-4.12M | $-4.71M | $-4.32M |
| Low Forecast | $-3.53M | $-3.83M | $-4.12M | $-3.83M | $-4.12M | $-4.71M | $-4.32M |
| Surprise % | - | - | - | - | - | - | - |
Immix Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMMX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Immix Biopharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Immix Biopharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMMX last annual SG&A of $NaN (undefined).
Immix Biopharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.12 | $-0.13 | $-0.14 | $-0.13 | $-0.14 | $-0.16 | $-0.15 |
| High Forecast | $-0.12 | $-0.13 | $-0.14 | $-0.13 | $-0.14 | $-0.16 | $-0.15 |
| Low Forecast | $-0.12 | $-0.13 | $-0.14 | $-0.13 | $-0.14 | $-0.16 | $-0.15 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Immix Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMMX previous annual EPS of $NaN (undefined).